Indianapolis, IN, United States of America

Scott Alan Frank

This inventor holds 7 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Eli Lilly and Company, Other. Active years: 1995-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott Alan Frank. Retrieved from https://idiyas.com/inventor/scott-alan-frank

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 11)

% Patents Active = 42.9

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 91(Granted Patents)

Location History:

Lebanon, IN (US) (1995)
Provo, UT (US) (2013)
Indianapolis, IN (US) (2009 - 2024)

Company Filing History:

5 out of 4,509

Eli Lilly and Company

patents

1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071423 - Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate (2024-08-27),

2. 11827618 - Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate (2023-11-28),

3. 8485101 - Reusable grenade (2013-07-16),

4. 8299060 - [object Object] (2012-10-30),

5. 8217032 - Selective estrogen receptor modulators for the treatment of vasomotor symptoms (2012-07-10),

6. 7585977 - Selective estrogen receptor modulators containing a phenylsulfonyl group (2009-09-08),

7. 5434171 - Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and (1995-07-18),

Title: Scott Alan Frank: Innovator in Pharmaceutical Processes

Introduction

Scott Alan Frank is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work primarily focuses on the large-scale preparation of complex chemical compounds.

Latest Patents

Among his latest patents are processes and intermediates for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate. These embodiments provide processes for the preparation of this compound and formulations such as tablets. The tablets include various dosages, including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of the compound.

Career Highlights

Scott has worked with prominent companies in the pharmaceutical industry, including Eli Lilly and Company. His experience in these organizations has allowed him to develop innovative processes that enhance the efficiency of drug production.

Collaborations

Some of his notable coworkers include Robert Dean Dally and Jeffrey A Dodge. Their collaboration has contributed to the advancement of pharmaceutical technologies.

Conclusion

Scott Alan Frank's work exemplifies innovation in the pharmaceutical sector, particularly in the preparation of complex compounds. His contributions continue to impact the industry positively.

Profile summary based on public USPTO records.